Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

7,302 total articles

Central Bancompany CEO Buys $979,880 in Class A Shares

Central Bancompany CEO Buys $979,880 in Class A Shares

Central Bancompany CEO Ross John Thomas purchased 40,000 Class A shares on February 6, 2026, paying a weighted average of $24.497 per share for a total of $979,880. The transaction, filed on a Form 4 with the SEC, leaves him with direct ownership of 82,000 shares and indirect ownership of 401,450 shares via Central Trust Company for joint benefit. …

Ralliant Director Adds to Stake as Company Reports Major Goodwill Charge and Mixed Analyst Reactions

Ralliant Director Adds to Stake as Company Reports Major Goodwill Charge and Mixed Analyst Reactions

Ralliant Corp director Moorthy Ganesh acquired 2,000 shares on February 6, 2026, investing $79,480. The transaction comes amid a $1.44 billion goodwill impairment tied to EA Elektro-Automatik and varied analyst adjustments to price targets following a guidance miss and recent corporate results. The board also approved a small quarterly dividend pay…

Merck Animal Health President Disposes of $4.56M in MRK Shares

Merck Animal Health President Disposes of $4.56M in MRK Shares

Richard R. DeLuca, Executive Vice President and President of Merck Animal Health, sold 37,685 shares of Merck & Co. Inc. (MRK) common stock on February 6, 2026, at a weighted average price of $120.9241 per share, generating proceeds of $4,557,024. The sale left DeLuca with 160,173.834 shares directly owned. In the same period, several analyst firms…

Protagonist Therapeutics Director Disposes of $1.67M in Stock; Exercises Options Ahead of Regulatory Milestones

Protagonist Therapeutics Director Disposes of $1.67M in Stock; Exercises Options Ahead of Regulatory Milestones

William D. Waddill, a director at Protagonist Therapeutics (PTGX), sold 20,000 shares on February 6, 2026, for about $1.67 million and concurrently exercised options to acquire an additional 20,000 shares at $8.31 each. The transactions leave him with 7,825 directly held shares. The moves coincide with a flurry of analyst updates after Protagonist …

Regal Rexnord Director Executes $1.71M Stock Sale Under 10b5-1 Plan

Regal Rexnord Director Executes $1.71M Stock Sale Under 10b5-1 Plan

Director Curtis W. Stoelting sold 9,000 shares of Regal Rexnord (RRX) stock on February 4 and 5, 2026, under a pre-established Rule 10b5-1 trading arrangement, realizing $1.71 million. The company recently reported fourth-quarter 2025 results that beat revenue and adjusted earnings expectations, and KeyBanc raised its price target to $200 while kee…

FirstCash CFO Sells $1.31 Million in Stock Under Prearranged Plan

FirstCash CFO Sells $1.31 Million in Stock Under Prearranged Plan

FirstCash Holdings Executive Vice President and CFO R. Douglas Orr sold 7,500 shares of company stock on February 5, 2026, generating $1,313,940 in proceeds across three transactions executed under a pre-established 10b5-1 plan. The trades leave Orr and related trusts and partnerships with substantial holdings, while Canaccord Genuity reaffirmed a …